Evidence-based acute bronchitis therapy

J Pharm Pract. 2012 Dec;25(6):586-90. doi: 10.1177/0897190012460826. Epub 2012 Oct 16.

Abstract

Acute bronchitis is a disease characterized by inflammation of the large airways within the lung accompanied by a cough lasting from 1 to 3 weeks. The inflammation occurs as a result of an airway infection or environmental trigger, with viral infections accounting for an estimated 89% to 95% of cases. Symptomatic treatment of cough is primarily required for patients, though in most cases the condition is self-limiting. Therapy consists of both nonpharmacological and pharmacological options to include antibiotics and antivirals, antitussive agents, protussive agents, and beta-2-agonists. This article reviews the treatment options for acute bronchitis and recommends criteria for use.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Adrenergic beta-2 Receptor Agonists / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Antitussive Agents / therapeutic use*
  • Antiviral Agents / therapeutic use*
  • Bronchitis / complications
  • Bronchitis / drug therapy*
  • Bronchitis / physiopathology
  • Clinical Trials as Topic
  • Cough / drug therapy*
  • Cough / etiology
  • Cough / physiopathology
  • Evidence-Based Medicine
  • Humans
  • Treatment Outcome

Substances

  • Adrenergic beta-2 Receptor Agonists
  • Anti-Bacterial Agents
  • Antitussive Agents
  • Antiviral Agents